Bent Ejlertsen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1802394/publications.pdf

Version: 2024-02-01

112 papers	6,947 citations	93792 39 h-index	73587 79 g-index
112 all docs	112 docs citations	112 times ranked	11504 citing authors

#	Article	IF	Citations
1	The Incidence of Breast Cancer Recurrence 10-32 Years After Primary Diagnosis. Journal of the National Cancer Institute, 2022, 114, 391-399.	3.0	114
2	A catalog of curated breast cancer genes. Breast Cancer Research and Treatment, 2022, 191, 431-441.	1.1	3
3	Survival in Women Diagnosed With Breast Cancer During Pregnancy. Clinical Breast Cancer, 2022, 22, e517-e525.	1.1	5
4	Use of betaâ€blockers and risk of contralateral breast cancer. International Journal of Cancer, 2022, , .	2.3	1
5	First-Line Treatment of HER2-Positive Metastatic Breast Cancer With Dual Blockade Including Biosimilar Trastuzumab (SB3): Population-Based Real-World Data From the DBCG. Breast Cancer: Basic and Clinical Research, 2022, 16, 117822342210869.	0.6	3
6	Mortality After Late Breast Cancer Recurrence in Denmark. Journal of Clinical Oncology, 2022, 40, 1450-1463.	0.8	14
7	Single-nucleotide polymorphisms and the effectiveness of taxane-based chemotherapy in premenopausal breast cancer: a population-based cohort study in Denmark. Breast Cancer Research and Treatment, 2022, , 1.	1.1	0
8	Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. Clinical Breast Cancer, 2021, 21, 80-91.e7.	1.1	140
9	Clinical behavior of recurrent hormone receptorâ€“positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1â€98 clinical trial. Cancer, 2021, 127, 700-708.	2.0	2
10	Clinical implications of intrinsic molecular subtypes of breast cancer for sentinel node status. Scientific Reports, 2021, 11, 2259.	1.6	13
11	Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer. British Journal of Cancer, 2021, 125, 1388-1398.	2.9	11
12	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Annals of Oncology, 2021, 32, 1216-1235.	0.6	354
13	Early Discontinuation of Endocrine Therapy and Recurrence of Breast Cancer among Premenopausal Women. Clinical Cancer Research, 2021, 27, 1421-1428.	3.2	19
14	A careful reassessment of anthracycline use in curable breast cancer. Npj Breast Cancer, 2021, 7, 134.	2.3	25
15	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.4	39
16	Prediction of fulvestrant efficacy in patients with advanced breast cancer: retrospective-prospective evaluation of the predictive potential of a multigene expression assay. Breast Cancer, 2020, 27, 266-276.	1.3	2
17	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	1.1	82
18	Rates of re-excision and conversion to mastectomy after breast-conserving surgery with or without oncoplastic surgery: a nationwide population-based study. British Journal of Surgery, 2020, 107, 1762-1772.	0.1	17

#	Article	IF	Citations
19	Induction of PIK3CA alterations during neoadjuvant letrozole may improve outcome in postmenopausal breast cancer patients. Breast Cancer Research and Treatment, 2020, 184, 123-133.	1.1	2
20	Breast cancer survival in Nordic BRCA2 mutation carriersâ€"unconventional association with oestrogen receptor status. British Journal of Cancer, 2020, 123, 1608-1615.	2.9	8
21	Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial. Breast Cancer Research, 2020, 22, 46.	2.2	27
22	Physical deterioration and adaptive recovery in physically inactive breast cancer patients during adjuvant chemotherapy: a randomised controlled trial. Scientific Reports, 2020, 10, 9710.	1.6	30
23	The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients. Npj Breast Cancer, 2020, 6, 7.	2.3	17
24	Characterization of the Cancer Spectrum in Men With GermlineBRCA1andBRCA2Pathogenic Variants. JAMA Oncology, 2020, 6, 1218.	3.4	48
25	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	0.6	32
26	Population-based Study of Prosigna-PAM50 and Outcome Among Postmenopausal Women With Estrogen Receptor-positive and HER2-negative Operable Invasive Lobular or Ductal Breast Cancer. Clinical Breast Cancer, 2020, 20, e423-e432.	1.1	17
27	Leukocyte nadir as a predictive factor for efficacy of adjuvant chemotherapy in breast cancer. Results from the prospective trial SBG 2000â€"1. Acta OncolÃ³gica, 2020, 59, 825-832.	0.8	5
28	Metabolic Pathway Analysis and Effectiveness of Tamoxifen in Danish Breast Cancer Patients. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 582-590.	1.1	4
29	Germline RBBP8 variants associated with early-onset breast cancer compromise replication fork stability. Journal of Clinical Investigation, 2020, 130, 4069-4080.	3.9	12
30	Heavy-load resistance exercise during chemotherapy in physically inactive breast cancer survivors at risk for lymphedema: a randomized trial. Acta OncolÃ³gica, 2019, 58, 1667-1675.	0.8	17
31	Whole genome sequencing of breast cancer. Apmis, 2019, 127, 303-315.	0.9	23
32	Overcoming Treatment Toxicity through Sequential Therapy. Cancer Cell, 2019, 35, 821-822.	7.7	4
33	Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene. BMC Cancer, 2019, 19, 573.	1.1	4
34	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	5.8	90
35	Subtypes in BRCA-mutated breast cancer. Human Pathology, 2019, 84, 192-201.	1.1	22
36	Is DBCG abreast of new developments?. Acta OncolÃ³gica, 2018, 57, 1-2.	0.8	17

#	Article	IF	Citations
37	Longâ€term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial. European Journal of Heart Failure, 2018, 20, 1447-1453.	2.9	46
38	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	1.1	224
39	Heavy-Load Lifting. Medicine and Science in Sports and Exercise, 2018, 50, 187-195.	0.2	21
40	Molecular subtyping of breast cancer improves identification of both high and low risk patients. Acta OncolÃ³gica, 2018, 57, 58-66.	0.8	12
41	Two years of tamoxifen or no adjuvant systemic therapy for patients with high-risk breast cancer: long-term follow-up of the Copenhagen breast cancer trial. Acta OncolÃ³gica, 2018, 57, 26-30.	0.8	2
42	Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG). Acta OncolÃ³gica, 2018, 57, 31-37.	0.8	13
43	Mortality and recurrence rates among systemically untreated high risk breast cancer patients included in the DBCG 77 trials. Acta OncolÃ³gica, 2018, 57, 135-140.	0.8	5
44	Breast conserving surgery versus mastectomy: overall and relative survivalâ€”a population based study by the Danish Breast Cancer Cooperative Group (DBCG). Acta OncolÃ³gica, 2018, 57, 19-25.	0.8	79
45	The occurrence of fractures after adjuvant treatment of breast cancer: a DBCG register study. Acta OncolÃ³gica, 2018, 57, 141-145.	0.8	3
46	Provision of data from the clinical database and of biological material from the tumor bank of the Danish Breast Cancer Cooperative Group 2008â€“2017. Acta OncolÃ³gica, 2018, 57, 154-156.	0.8	2
47	Characterization of basal-like subtype in a Danish consecutive primary breast cancer cohort. Acta OncolÃ³gica, 2018, 57, 51-57.	0.8	0
48	Quality of life and care needs in women with estrogen positive metastatic breast cancer: a qualitative study. Acta OncolÃ³gica, 2018, 57, 146-151.	0.8	21
49	Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration. Acta OncolÃ³gica, 2018, 57, 3-12.	0.8	14
50	The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007â€“2016. Acta OncolÃ³gica, 2018, 57, 13-18.	0.8	44
51	PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptorâ€“Positive Early Breast Cancer. Journal of Clinical Oncology, 2018, 36, 735-740.	0.8	108
52	Low-dose aspirin use and risk of contralateral breast cancer: a Danish nationwide cohort study. Preventive Medicine, 2018, 116, 186-193.	1.6	10
53	Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptorâ€“Positive, HER2-Negative Advanced Breast Cancer. JAMA Oncology, 2018, 4, 1367.	3.4	67
54	Cohort Profile: the Predictors of Breast Cancer Recurrence (ProBe CaRE) Premenopausal Breast Cancer Cohort Study in Denmark. BMJ Open, 2018, 8, e021805.	0.8	11

#	Article	IF	Citations
55	The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer. Breast Cancer Research, 2018, 20, 79.	2.2	41
56	The ability of PAM50 risk of recurrence score to predict 10-year distant recurrence in hormone receptor-positive postmenopausal women with special histological subtypes. Acta OncolÃ³gica, 2018, 57, 44-50.	0.8	10
57	Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study.. Journal of Clinical Oncology, 2018, 36, 1005-1005.	0.8	2
58	Timing of initiation of neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ hormone receptor (HR)-negative breast cancer: Exploratory analyses from the phase III ExteNET trial.. Journal of Clinical Oncology, 2018, 36, 549-549.	0.8	3
59	Liposomal cisplatin response prediction in heavily pretreated breast cancer patients: A multigene biomarker in a prospective phase 2 study.. Journal of Clinical Oncology, 2018, 36, e13077-e13077.	0.8	4
60	Clinical characteristics and registry-validated extended pedigrees of germline TP53 mutation carriers in Denmark. PLoS ONE, 2018, 13, e0190050.	1.1	6
61	Genomic profiling of tumors from patients with germline BRCA mutations.. Journal of Clinical Oncology, 2018, 36, 1533-1533.	0.8	1
62	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356
63	Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity. American Journal of Epidemiology, 2017, 185, 75-85.	1.6	30
64	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	9.4	289
65	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 1688-1700.	5.1	451
66	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	1.1	18
67	Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial. Journal of Clinical Oncology, 2017, 35, 2639-2646.	0.8	43
68	Danish Breast Cancer Cooperative Group. Clinical Epidemiology, 2016, Volume 8, 445-449.	1.5	76
69	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS ONE, 2016, 11, e0158801.	1.1	10
70	Importance of margin width in breastâ€conserving treatment of early breast cancer. Journal of Surgical Oncology, 2016, 113, 609-615.	0.8	29
71	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64.	2.2	31
72	A randomized cross-over trial to detect differences in arm volume after low- and heavy-load resistance exercise among patients receiving adjuvant chemotherapy for breast cancer at risk for arm lymphedema: study protocol. BMC Cancer, 2016, 16, 517.	1.1	8

#	Article	IF	Citations
73	Risk of non-sentinel node metastases in patients with symptomatic cancers compared to screen-detected breast cancers. Acta OncolÃ³gica, 2016, 55, 455-459.	0.8	2
74	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15.	2.2	88
75	Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant. ESMO Open, 2016, 1, e000062.	2.0	43
76	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€“ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	5.8	78
77	Identification of six pathogenic RAD51C mutations via mutational screening of 1228 Danish individuals with increased risk of hereditary breast and/or ovarian cancer. Breast Cancer Research and Treatment, 2016, 155, 215-222.	1.1	25
78	Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2016, 17, 367-377.	5.1	444
79	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	9.4	125
80	Improvements in breast cancer survival between 1995 and 2012 in Denmark: The importance of earlier diagnosis and adjuvant treatment. Acta OncolÃ³gica, 2016, 55, 24-35.	0.8	33
81	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	0.6	18
82	The challenge of preserving cardiorespiratory fitness in physically inactive patients with colon or breast cancer during adjuvant chemotherapy: a randomised feasibility study. BMJ Open Sport and Exercise Medicine, 2015, 1, e000021.	1.4	30
83	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	2.2	26
84	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. PLoS ONE, 2015, 10, e0120020.	1.1	34
85	Predicting Anthracycline Benefit: TOP2A and CEP17â€”Not Only but Also. Journal of Clinical Oncology, 2015, 33, 1680-1687.	0.8	55
86	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	9.4	221
87	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	3.8	390
88	Prognostic significance of axillary dissection in breast cancer patients with micrometastases or isolated tumor cells in sentinel nodes: a nationwide study. Breast Cancer Research and Treatment, 2015, 153, 599-606.	1.1	16
89	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	1.1	22
90	Functional characterization of BRCA1 gene variants by mini-gene splicing assay. European Journal of Human Genetics, 2014, 22, 1362-1368.	1.4	58

#	Article	IF	Citations
91	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	1.5	47
92	Incidence of metachronous contralateral breast cancer in Denmark 1978â€“2009. International Journal of Epidemiology, 2014, 43, 1855-1864.	0.9	31
93	Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer. Acta OncolÃ³gica, 2014, 53, 174-185.	0.8	29
94	Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial. European Journal of Cancer, 2014, 50, 1412-1421.	1.3	20
95	Prospective Validation of HLA-DRB1*07:01 Allele Carriage As a Predictive Risk Factor for Lapatinib-Induced Liver Injury. Journal of Clinical Oncology, 2014, 32, 2296-2303.	0.8	69
96	Risk of contralateral breast cancer after tamoxifen use among Danish women. Annals of Epidemiology, 2014, 24, 843-848.	0.9	17
97	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	9.4	493
98	Relative effectiveness of letrozole alone or in sequence with tamoxifen for patients diagnosed with invasive lobular carcinoma.. Journal of Clinical Oncology, 2013, 31, 529-529.	0.8	4
99	Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status. Molecular Oncology, 2012, 6, 88-97.	2.1	16
100	HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncology, The, 2011, 12, 1134-1142.	5.1	165
101	HER2, TOP2A, and TIMP-1 and Responsiveness to Adjuvant Anthracycline-Containing Chemotherapy in High-Risk Breast Cancer Patients. Journal of Clinical Oncology, 2010, 28, 984-990.	0.8	72
102	Population-Based Study of Peritumoral Lymphovascular Invasion and Outcome Among Patients With Operable Breast Cancer. Journal of the National Cancer Institute, 2009, 101, 729-735.	3.0	85
103	The value ofTOP2Agene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D. Acta OncolÃ³gica, 2008, 47, 725-734.	0.8	101
104	The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta OncolÃ³gica, 2008, 47, 506-524.	0.8	232
105	Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: Indirect comparison of dose and schedule in DBCG trials 77, 82, and 89. Acta OncolÃ³gica, 2008, 47, 662-671.	0.8	11
106	DBCG trial 89B comparing adjuvant CMF and ovarian ablation: Similar outcome for eligible but non-enrolled and randomized breast cancer patients. Acta OncolÃ³gica, 2008, 47, 709-717.	0.8	4
107	Improved outcome from substituting methotrexate with epirubicin: Results from a randomised comparison of CMF versus CEF in patients with primary breast cancer. European Journal of Cancer, 2007, 43, 877-884.	1.3	55
108	Similar Efficacy for Ovarian Ablation Compared With Cyclophosphamide, Methotrexate, and Fluorouracil: From a Randomized Comparison of Premenopausal Patients With Node-Positive, Hormone Receptorâ€“Positive Breast Cancer. Journal of Clinical Oncology, 2006, 24, 4956-4962.	0.8	52

#	Article	IF	Citations
109	Retrospective Analysis of Topoisomerase IIa Amplifications and Deletions As Predictive Markers in Primary Breast Cancer Patients Randomly Assigned to Cyclophosphamide, Methotrexate, and Fluorouracil or Cyclophosphamide, Epirubicin, and Fluorouracil: Danish Breast Cancer Cooperative Group. Journal of Clinical Oncology, 2005, 23, 7483-7490.	0.8	292
110	Phase III Study of Intravenous Vinorelbine in Combination With Epirubicin Versus Epirubicin Alone in Patients With Advanced Breast Cancer: A Scandinavian Breast Group Trial (SBG9403). Journal of Clinical Oncology, 2004, 22, 2313-2320.	0.8	57
111	Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta OncolÃ³gica, 2004, 43, 35-42.	0.8	65
112	Molecular cytogenetic analysis of a nontumorigenic human breast epithelial cell line that eventually turns tumorigenic: Validation of an analytical approach combining karyotyping, comparative genomic hybridization, chromosome painting, and single-locus fluorescence in situ hybridization. Genes Chromosomes and Cancer, 1997, 20, 30-37.	1.5	9